Current evidence demonstrates that platelet-rich plasma provides only short-term functional improvement in chronic midportion Achilles tendinopathy, with no significant long-term or structural benefits and no additional clinical advantage as a surgical adjunct. Consequently, PRP should not be considered a routine treatment, and clinicians should prioritize evidence-based rehabilitation while counseling patients regarding its limited and transient effects. Future research must focus on establishing standardized PRP protocols, conducting large multicenter trials, and investigating optimized formulations and combination therapies to potentially enhance therapeutic outcomes.
He et al. (Wed,) studied this question.